
Massive Bio is an AI-powered platform that connects cancer patients with clinical trials, enhancing access to life-saving treatments. The company leverages advanced technology and real-time data to streamline patient recruitment and trial matching, ensuring that patients receive timely and appropriate care. With over 160,000 onboarded patients and partnerships with leading pharmaceutical companies, Massive Bio is positioned as a key player in the oncology space, addressing barriers to trial enrollment and improving patient outcomes globally.

Massive Bio is an AI-powered platform that connects cancer patients with clinical trials, enhancing access to life-saving treatments. The company leverages advanced technology and real-time data to streamline patient recruitment and trial matching, ensuring that patients receive timely and appropriate care. With over 160,000 onboarded patients and partnerships with leading pharmaceutical companies, Massive Bio is positioned as a key player in the oncology space, addressing barriers to trial enrollment and improving patient outcomes globally.
What they do: AI-enabled platform that matches cancer patients to clinical trials and provides real-world data and trial-activation services
Founding year: 2014/2015 (sources cite both 2014 and 2015)
Scale: Reported six-figure patient base (120k–160k+ patients) and partnerships with pharma/CROs
Recent funding: Reported total funding ≈ $23.8M; disclosed rounds include $2.6M and $9M financings
Headquarters: New York City
Clinical trial enrollment and patient-trial matching in oncology
2014
Hospitals and Health Care
2600000
Announced $2.6M financing; reported at the time to bring total funding to $6.6M
9000000
Announced $9M financing co-led by Revo Capital and Kenan Turnacioglu with participation from DEG
“Includes strategic/impact investors and development finance participants such as Revo Capital, Kenan Turnacioglu, IFC, DEG, ImpactAssets, Cavendish Impact Foundation, SiteGround Capital, and philanthropic investors”
| Company |
|---|